Robert Wong, VP and Chief Accounting Officer of Retension Pharmaceuticals, Inc., filed an initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing no securities held as of his event date of November 2, 2026.

Key Highlights

  • Reporting person: Robert Wong, identified as VP, Chief Accounting Officer of Retension Pharmaceuticals, Inc. (NASDAQ:RTSN).
  • Event date: The date of event requiring the statement is listed as November 2, 2026.
  • No securities owned: The filing states explicitly, "No securities are beneficially owned."
  • No non-derivative holdings: Table I, covering non-derivative securities, contains no entries.
  • No derivative holdings: Table II, covering derivative securities such as options or warrants, also contains no entries.
  • Signed by attorney-in-fact: The form was signed by Alex Schwartz as attorney-in-fact on November 4, 2026, pursuant to an Exhibit 24 Power of Attorney.

Robert Wong's Initial Beneficial Ownership Filing for Retension Pharmaceuticals

Robert Wong filed a Form 3 initial statement of beneficial ownership with the U.S. Securities and Exchange Commission on November 4, 2026, in connection with his role as VP and Chief Accounting Officer at Retension Pharmaceuticals, Inc., listed on NASDAQ under the symbol RTSN. The filing was triggered by an event dated November 2, 2026, which required him to report his initial beneficial ownership position.

According to the filing, Wong holds no securities in Retension Pharmaceuticals. Both Table I, which covers non-derivative securities beneficially owned directly or indirectly, and Table II, which covers derivative securities such as puts, calls, warrants, options, and convertible securities, are entirely blank. The filing states plainly: "No securities are beneficially owned."

The form was not filed as an amendment, and it was filed by one reporting person rather than a group. The signature block reflects that Alex Schwartz signed the document as attorney-in-fact on November 4, 2026, pursuant to a Power of Attorney listed as Exhibit 24. Wong's address is listed as 1104 West Broad Street, Suite 1029, Falls Church, Virginia 22046.

What Was Disclosed

Robert Wong, VP and Chief Accounting Officer of Retension Pharmaceuticals, Inc. (NASDAQ:RTSN), filed an initial beneficial ownership statement dated November 4, 2026, disclosing no direct or indirect holdings of any securities, derivative or otherwise, in the company.